1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemECevipabulin fumarateCat. No.: HY-14949CCAS No.: 849550-67-0Synonyms: TTI-237 fumarate分式: CHClFNO分量: 580.89作靶點: Microtubule/Tubulin作通路: Cell Cycle/DNA Damage; Cytoskeleton儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months

2、-20C 1 month溶解性數據體外實驗 DMSO : 50 mg/mL (86.07 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.7215 mL 8.6075 mL 17.2150 mL5 mM 0.3443 mL 1.7215 mL 3.4430 mL10 mM 0.1721 mL 0.8607 mL 1.7215 mL請根據產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Cevipabulin fumara

3、te (TTI-237 fumarate)種微管活性的、服有效的抗腫瘤化合物，可抑制 3H長春堿與微管蛋的結合，對癌細胞的 IC50 值為 18-40 nM 1 2。IC50 & Target IC50: 18-40 nM (microtubule in human tumor cells) 1.體外研究Cevipabulin (0-50 nM, 72 hours) shows good activity (between 18 and 40 nM IC50 values) on cell lines from1/3 Master of Small Molecules 您邊的抑制劑師www.M

4、edChemEovarian, breast, prostate, and cervical tumors 1.Flow cytometry experiments reveal that, Cevipabulin (TTI-237) at low concentrations (20-40 nM) producessub-G1 nuclei and, at concentrations above 50 nM, it causes a strong G2-M block 1.Cell Cytotoxicity Assay 1Cell Line: Human cancer cell lines

5、 (SK-OV-3, MDA-MB-435, MDA-MB-468, LnCaP, and Helacells).Concentration: 0-50 nMIncubation Time: 72 hoursResult: The IC50 values are 248 nM, 214 nM, 186 nM, 227 nM and 40 nM in SK-OV-3,MDA-MB-435, MDA-MB-468, LnCaP and Hela cells.體內研究 Cevipabulin (TTI-2370)( 5, 10, 15, and 20 mg/kg, every 4 days for

6、4 cycles, in mice) is active by i.v. and p.o.administration against human tumor xenografts, showing dose-dependent effects, with good antitumoractivity at 20 and 15 mg/kg 1.Animal Model: Athymic nu/nu female mice implanted s.c. in the flank with 1107 LoVo human colonadenocarcinoma cells 1.Dosage: 5,

7、 10, 15, and 20 mg/kgAdministration: I.V. injection every 4 days for 4 cycles.Result: The compound showed dose-dependent effects, with good antitumor activity at 20 and15 mg/kg.Animal Model: Athymic nu/nu female mice implanted s.c. in the flank with 1106 U87-MG humanglioblastoma cells 1.Dosage: 25 m

8、g/kg.Administration: P.O. or I.V. on days 0, 7, 14.Result: The compound was active by p.o. or i.v. administration against human tumor xenografts.戶使本產品發(fā)表的科研獻 Biochem Biophys Res Commun. 2019 Aug 27;516(3):760-764.See more customer validations on HYPERLINK / www.MedChemEREFERENCES2/3 Master of Small M

9、olecules 您邊的抑制劑師www.MedChemE1. Beyer CF, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008 Apr 1;68(7):2292-300.2. Beyer CF, et al. The microtubule-active antitumor compound TTI-237 has both DB01229-like and Leurocristine-like properties. CancerChemother Pharmacol. 2009 Sep;64(4):681-9.McePdfHeightCaution: Product has not been fully validated for med